Literature DB >> 13982999

The immunological basis for non-infective Rous sarcomas.

H RUBIN.   

Abstract

Entities:  

Keywords:  IMMUNITY; ROUS SARCOMA; ROUS SARCOMA VIRUS

Mesh：

Year:  1962        PMID： 13982999     DOI： 10.1101/sqb.1962.027.001.042

Source DB:  PubMed          Journal:  Cold Spring Harb Symp Quant Biol        ISSN： 0091-7451


× No keyword cloud information.
  8 in total

1.  The defectiveness of Rous sarcoma virus.

Authors:  H HANAFUSA; T HANAFUSA; H RUBIN
Journal:  Proc Natl Acad Sci U S A       Date:  1963-04       Impact factor: 11.205

2.  Enhancement of avian sarcoma virus-induced tumor growth after pretreatment with BCG.

Authors:  M A Wainberg; E Israel
Journal:  Infect Immun       Date:  1978-11       Impact factor: 3.441

3.  Immunological responsiveness against tumors induced by avian sarcoma virus: reduced expression of pp60src kinase activity in regressing tumors.

Authors:  L Poulin; L Grisé-Miron; M A Wainberg
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

4.  Plasma cell and lymphocytic reaction in the Syrian hamster to transplanted homologous tumor cells transformed in vitro "spontaneously" or by SV 40.

Authors:  G T Diamandopoulos
Journal:  Arch Gesamte Virusforsch       Date:  1967

Review 5.  Cell-mediated tumour immunity in patients with transitional cell carcinoma of the urinary bladder.

Authors:  J Bubeník
Journal:  Int Urol Nephrol       Date:  1975       Impact factor: 2.370

6.  Genetic interaction between non-MHC T- and B-cell alloantigens in response to Rous sarcomas in chickens.

Authors:  D G Gilmour; W M Collins; T L Fredericksen; W E Urban; P F Ward; N L DiFronzo
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

7.  EVOLUTION OF THE IMMUNE RESPONSE. I. THE PHYLOGENETIC DEVELOPMENT OF ADAPTIVE IMMUNOLOGIC RESPONSIVENESS IN VERTEBRATES.

Authors:  B W PAPERMASTER; R M CONDIE; J FINSTAD; R A GOOD
Journal:  J Exp Med       Date:  1964-01-01       Impact factor: 14.307

8.  Studies on the heterologous immunogenicity of a methanol-insoluble fraction of attenuated tubercle bacilli (BCG). II. Protection against tumor isografts.

Authors:  D W Weiss; R S Bonhag; P Leslie
Journal:  J Exp Med       Date:  1966-12-01       Impact factor: 14.307
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.